Rapid Steroid Dosing Does Not Increase Fracture Risk in Elderly Asthmatics

A retrospective cohort study published in BMC Geriatrics reports that the speed at which older adults with asthma accumulate a high cumulative dose of systemic corticosteroids does not significantly alter their risk of osteoporotic fractures. The research, conducted by Siin Kim, Donghyun Pyun, and Hae Sun Suh, specifically compares patients who reached a cumulative prednisolone equivalent dose of at least 450 mg within 90 days or less against those who took longer than 90 days to reach the same threshold. The investigation utilized data from the Health Insurance Review and Assessment Service Database in Korea to identify patients aged 65 years and older who were diagnosed with asthma in 2016 and treated with systemic corticosteroids within six months of diagnosis.

The primary objective was to evaluate the risk of osteoporotic fractures according to the intensity of dose accumulation, distinguishing between rapid and gradual attainment of the same cumulative dose. By focusing on this specific window and population, the researchers aimed to provide real-world evidence regarding the safety of different corticosteroid prescribing strategies in elderly patients managing asthma. To ensure a fair comparison, the researchers categorized the 6,342 eligible patients into high- and low-intensity groups based on the time taken to reach the 450 mg cumulative dose threshold.

The high-intensity group comprised 4,391 patients who achieved this dose within 90 days or less, while the low-intensity group included 1,951 patients who took more than 90 days. Recognizing that various factors could influence fracture risk, the team employed propensity score matching to balance confounding variables between the two cohorts. This statistical method created comparable groups, allowing for a more precise assessment of the relationship between dosing speed and fracture outcomes.

After propensity score matching, each group consisted of 1,783 patients, ensuring that baseline characteristics were sufficiently balanced for analysis. The primary outcome measured was the incidence of osteoporotic fractures during the follow-up period. The results indicated that the fracture incidence rate was 50.18 per 1,000 person-years in the high-intensity group and 52.58 per 1,000 person-years in the low-intensity group.

Although the rate was numerically slightly lower in the rapid dosing group, the difference was not statistically significant, suggesting that the speed of dose accumulation did not drive a meaningful change in fracture frequency. The study calculated a hazard ratio of 0.95 for the high-intensity group compared to the low-intensity group, with a 95% confidence interval ranging from 0.78 to 1.15. Because this confidence interval includes 1.0, the researchers concluded that there was no significant difference in fracture risk between the two groups.

This finding implies that, within the context of a cumulative dose of at least 450 mg, the rapid attainment of this dose does not confer a higher fracture risk compared to a slower accumulation over a longer period. To validate the robustness of these findings, the researchers conducted sensitivity analyses using multivariate adjustments and competing risk approaches. These additional statistical methods accounted for other potential causes of death or events that might compete with the occurrence of fractures, further confirming that the lack of a significant difference in fracture risk was not an artifact of the primary analysis.

The consistency of the results across different analytical frameworks strengthens the conclusion that the speed of corticosteroid dose accumulation does not significantly alter the risk of osteoporotic fractures in this specific population of elderly asthmatic patients. The authors note that the study provides exploratory real-world evidence that can inform future evaluations of reimbursement criteria for osteoporosis medications in short-term corticosteroid users. However, the retrospective nature of the study and its reliance on administrative data limit the ability to establish causality.

The study specifically examines patients who reached a cumulative dose of at least 450 mg, so the findings may not apply to patients receiving lower total doses or different medication regimens. The current evidence suggests that careful monitoring of fracture risk is warranted for patients receiving high cumulative doses, regardless of the speed of administration, but it does not support the idea that rapid dosing is inherently more dangerous than gradual dosing for fractures.

Subject of Research: Osteoporotic fracture risk in elderly asthmatics based on systemic corticosteroid dosing speed

Article Title: Risk of osteoporotic fractures in elderly asthmatic patients according to prescription patterns of systemic corticosteroid: a retrospective cohort study

Article References: Kim, S., Pyun, D., & Suh, H. S. (2026). Risk of osteoporotic fractures in elderly asthmatic patients according to prescription patterns of systemic corticosteroid: a retrospective cohort study. BMC Geriatrics. https://doi.org/10.1186/s12877-026-08378-7

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08378-7

Keywords: osteoporotic fractures, systemic corticosteroids, elderly asthma, retrospective cohort, dose accumulation, BMC Geriatrics, fracture risk, prescription patterns, Risk, osteoporotic, fractures, elderly